Stock OBD OXFORD BIODYNAMICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Oxford BioDynamics Plc Share Price

Equities

OBD

GB00BD5H8572

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 16:35:27 26/04/2024 BST 		5-day change 1st Jan Change
8.1 GBX -1.22% Intraday chart for Oxford BioDynamics Plc -9.90% -71.07%
04-03 Oxford BioDynamics reaches "important milestone" with new laboratory AN
04-03 Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test CI

Financials

Sales 2022 154K 192K 15.4M Sales 2023 510K 637K 51M Capitalization 74.85M 93.5M 7.49B
Net income 2022 -6M -7.5M -600M Net income 2023 -10M -12.49M -1B EV / Sales 2022 108 x
Net Debt 2022 5.14M 6.42M 514M Net Debt 2023 1.19M 1.49M 119M EV / Sales 2023 149 x
P/E ratio 2022
-1.71 x
P/E ratio 2023
-5.04 x
Employees 45
Yield 2022 *
-
Yield 2023
-
Free-Float 81.11%
More Fundamentals * Assessed data

Chart Oxford BioDynamics Plc

Dynamic Chart

Latest news about Oxford BioDynamics Plc

Oxford BioDynamics reaches "important milestone" with new laboratory AN
Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test CI
Oxford Biodynamics Raises GBP9.9 Million to Support EpiSwitch Product Line MT
FireAngel CFO resigns; ECR Minerals raises GBP585,000 AN
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal AN
Oxford BioDynamics plunges as annual loss widens; revenue up AN
Oxford BioDynamics plunge as annual profit rises; revenue up AN
Oxford BioDynamics shares plunge as annual revenue widens; revenue up AN
AIM WINNERS & LOSERS: James Cropper falls on lower outlook AN
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Revenue GBP510,000 MT
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Loss GBX-7.30 MT
Oxford BioDynamics Plc Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Oxford BioDynamics Appoints Steven Arrivo as Senior Vice President of Business and Corporate Development CI
FTSE 100 Edged Lower, Buoyed by Resilient Retail Sector DJ
Oxford BioDynamics director sells over 700,000 shares AN
More news

Analyst Recommendations on Oxford BioDynamics Plc

FTSE 100 Closes Down 1.4% on US Credit Rating Downgrade; BAE Outperforms DJ
Sterling Stands to Benefit From Higher Rates DJ
More recommendations

Press releases Oxford BioDynamics Plc

Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer AQ
Bupa UK to cover EpiSwitch® CiRT for customers with cancer BU
Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test AQ
Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test BU
Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK AQ
More press releases

News in other languages on Oxford BioDynamics Plc

Oxford BioDynamics Plc : accord trouvé avec une entreprise pharmaceutique américaine
More news

Quotes and Performance

1 day-1.22%
1 week-9.90%
Current month-13.83%
1 month-14.65%
3 months-48.73%
6 months-76.18%
Current year-71.07%
More quotes

Highs and lows

1 week
7.80
Extreme 7.8
9.80
1 month
7.80
Extreme 7.8
10.55
Current year
7.80
Extreme 7.8
36.90
1 year
7.80
Extreme 7.8
52.00
3 years
7.80
Extreme 7.8
85.00
5 years
7.80
Extreme 7.8
173.90
10 years
7.80
Extreme 7.8
278.82
More quotes

Managers and Directors - Oxford BioDynamics Plc

Managers TitleAgeSince
Alexandre Akoulitchev FOU
 Founder 62 22/04/07
Jon Burrows CEO
 Chief Executive Officer - 22/03/20
Paul Stockdale DFI
 Director of Finance/CFO - 14/09/17
Members of the board TitleAgeSince
Stephen Diggle BRD
 Director/Board Member 60 03/10/16
David Holbrook BRD
 Director/Board Member 63 04/04/19
Jon Burrows CEO
 Chief Executive Officer - 22/03/20
More insiders

Quotes

Date Price Change Volume
26/04/24 8.1 -1.22% 921,776
25/04/24 8.2 -8.89% 249,600
24/04/24 9 -0.99% 672,529
23/04/24 9.09 +3.30% 308,828
22/04/24 8.8 -2.11% 196,700

Delayed Quote London S.E., April 26, 2024 at 04:35 pm

More quotes

Company Profile

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Sector
Biotechnology & Medical Research
Calendar
27/05/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
OXFORD BIODYNAMICS PLC Stock Oxford BioDynamics Plc
-71.07% 20.41M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. OBD Stock